1. Home
  2. PLUS vs BEAM Comparison

PLUS vs BEAM Comparison

Compare PLUS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ePlus inc.

PLUS

ePlus inc.

HOLD

Current Price

$86.11

Market Cap

2.4B

Sector

Technology

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$28.96

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLUS
BEAM
Founded
1990
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.8B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
PLUS
BEAM
Price
$86.11
$28.96
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$48.09
AVG Volume (30 Days)
180.1K
1.4M
Earning Date
02-04-2026
02-24-2026
Dividend Yield
1.14%
N/A
EPS Growth
14.25
N/A
EPS
4.60
N/A
Revenue
$2,285,906,000.00
$55,701,000.00
Revenue This Year
$14.37
N/A
Revenue Next Year
$3.17
$26.52
P/E Ratio
$17.95
N/A
Revenue Growth
9.24
N/A
52 Week Low
$53.83
$13.53
52 Week High
$93.98
$35.25

Technical Indicators

Market Signals
Indicator
PLUS
BEAM
Relative Strength Index (RSI) 42.38 63.38
Support Level $87.62 $26.25
Resistance Level $90.10 $30.50
Average True Range (ATR) 2.28 1.49
MACD -0.69 -0.00
Stochastic Oscillator 16.27 68.91

Price Performance

Historical Comparison
PLUS
BEAM

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: